EGFR and non-small cell lung carcinoma: When tumor-bearing mice were treated with durvalumab alone, it did not suppress tumor growth compared with isotype control, which closely mimicked the limited therapeutic effect of anti–PD-1 and anti–PD-L1 antibodies on EGFR-mutated NSCLC.